About Camurus
Camurus is a company based in Lund (Sweden) founded in 1991. The company has 256 employees as of December 31, 2024. Camurus offers products and services including Opioid Dependence Treatment, Acromegaly Treatment, Neuroendocrine Tumors Treatment, and Polycystic Liver Disease Treatment. Camurus operates in a competitive market with competitors including Jazz Pharmaceuticals, GSK, C4 Therapeutics, Erasca and MiRagen, among others.
- Headquarter Lund, Sweden
- Employees 256 as on 31 Dec, 2024
- Stage Public
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Camurus Ab
-
Annual Revenue
$169.54 M (USD)8.78as on Dec 31, 2024
-
Net Profit
$38.84 M (USD)-0.71as on Dec 31, 2024
-
EBITDA
$43.84 M (USD)-11.15as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
256
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Camurus
Camurus is a publicly listed company on the OMXSTO with ticker symbol CAMX in Sweden, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Camurus
Camurus offers a comprehensive portfolio of products and services, including Opioid Dependence Treatment, Acromegaly Treatment, Neuroendocrine Tumors Treatment, and Polycystic Liver Disease Treatment.
Treatment for managing opioid dependence through innovative delivery systems.
Therapy for acromegaly to improve patient hormone regulation.
Solutions for treating neuroendocrine tumors effectively.
Medications targeting polycystic liver disease management.
People of Camurus
Unlock access to complete
Unlock access to complete
Funding Insights of Camurus
Detailed funding history for Camurus
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Camurus
Investment portfolio details for Camurus
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Camurus
Detailed financials for Camurus
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Camurus Comparisons
Peer comparison for Camurus
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Camurus
Camurus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, GSK, C4 Therapeutics, Erasca and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Camurus
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Camurus
Complete news archive for Camurus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Camurus
Camurus was founded in 1991.
Camurus is headquartered in Lund, Sweden.
As of Dec 31, 2024, the latest employee count at Camurus is 256.
Annual revenue of Camurus is $169.54M as on Dec 31, 2024.
Camurus is a Swedish, Public, drug discovery and development company focusing on serious chronic diseases. Their formulations are based on lipid phase nanostructures and utilize lyotropic liquid crystal structures for solubilization, stabilization, and delivery of active pharmaceutical substances. Their therapeutic areas include cancer, endocrinology, pain, metabolic disease and drug addiction. As on Dec.2016, they have 2 candidates in Phase III: CAM2038 (q1w, and q4w) for Opioid Dependence and CAM2038, which is a subcutaneous pre-filled injection depot of buprenorphine for chronic pain. Camarus has partnered with Breaburn pharma for these drugs. It also has a number of candidates under development, in partnership with Novartis.
Camurus's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Camurus offers Opioid Dependence Treatment, Acromegaly Treatment, Neuroendocrine Tumors Treatment, and Polycystic Liver Disease Treatment.
Yes, Camurus is publicly traded on OMXSTO under the ticker symbol CAMX.
The ticker symbol of Camurus is CAMX on OMXSTO.